{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:29:29Z","timestamp":1764052169473,"version":"3.45.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predictors. These variables were integrated to establish the FAAP scoring system, which demonstrated robust discriminative performance with AUC of 0.804 (95% CI: 0.703-0.893) and 0.799 (95% CI: 0.67-0.911) in the training and validation cohorts, respectively. Patients were stratified into three risk groups based on FAAP scores: low (FAAP &amp;lt; 0.7), intermediate (0.7 \u2264 FAAP &amp;lt; 2.2), and high (FAAP \u2265 2.2). Kaplan-Meier analyses revealed significant prognostic stratification for both OS and progression-free survival (PFS) across groups. Subgroup analyses confirmed the prognostic relevance of FAAP scores in key clinical subsets, including age, gender, extrahepatic metastasis status, viral hepatitis etiology, PVTT presence, and Child-Pugh stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The FAAP scoring system effectively predicted survival outcomes in HCC patients receiving TACE-sintilimab-bevacizumab therapy, which suggests its clinical utility for prognostic prediction. Further large prospective studies are required for external validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1692632","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:24:55Z","timestamp":1764051895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Liying","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoping","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000578","DOI":"10.1136\/bmjonc-2024-000578","article-title":"Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis","volume":"3","author":"Sun","year":"2024","journal-title":"BMJ Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-260","article-title":"Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO)","volume":"10","author":"Lu","year":"2021","journal-title":"Hepatobil Surg Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001229","article-title":"Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70018","article-title":"Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241297080","article-title":"The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local-regional therapy in unresectable hepatocellular carcinoma","volume":"16","author":"Zuo","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010035","article-title":"Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101295","article-title":"Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab","volume":"7","author":"Gairing","year":"2025","journal-title":"JHEP Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109771","article-title":"Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10613-x","article-title":"The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors","volume":"18","author":"Zeng","year":"2024","journal-title":"Hepatol Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2013.34611","article-title":"The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression","volume":"17","author":"Ko\u0142odziejczyk","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.5.1468.1468","article-title":"Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease","volume":"67","author":"VanDewater","year":"1986","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32835aef6b","article-title":"Higher prognostic value of soluble fibrin complexes than D-dimer and fibrin degradation product for disseminated intravascular coagulation in patients with liver cirrhosis","volume":"24","author":"Kim","year":"2013","journal-title":"Blood Coagul Fibrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16705-8","article-title":"Perioperative changes in serum transaminases levels predicts long-term survival following liver resection of hepatocellular carcinoma","volume":"32","author":"Lu","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.62347\/SXMJ5155","article-title":"Key prognostic factors in transarterial chemoembolization combined with sorafenib treatment for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"15","author":"Lei","year":"2025","journal-title":"Am J Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001691","article-title":"Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial","volume":"110","author":"Zhou","year":"2024","journal-title":"Int J Surg"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1692632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:24:55Z","timestamp":1764051895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1692632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1692632"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1692632","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"article-number":"1692632"}}